Company news

Mustang Bio, Inc. news in 2024

Mustang Bio, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Mustang Bio Receives Positive Listing Determination from Nasdaq

November 11, 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

November 6, 2024

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds Form 8 K

October 23, 2024

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

October 23, 2024

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 19, 2024

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of phase Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

June 18, 2024

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

June 16, 2024

Mustang Bio Announces Closing of $4 Million Public Offering

May 1, 2024

Mustang Bio Announces Pricing of $4 Million Public Offering

April 28, 2024

Costs Associated with Exit/Disposal - Form 8-K

April 12, 2024

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

March 27, 2024

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 10, 2024

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

March 6, 2024

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 10, 2024

Decks in 2024